3 imaging techniques are done in Hepatocellular Carcinoma - Clinical Trials Registry

Study Overview

Status

Unknown

Conditions

Hepatocellular Carcinoma

Intervention / Treatment

Other: 3 imaging techniques are done

Detailed Description

With the improvement of cirrhosis complications coverage, hepatocellular carcinoma (HCC) tend to become the main cause of mortality for cirrhotic patients. Currently, the incidence of the HCC increase in occidental country and hid global prognostic remain very bad. The main indication factor for a curative treatment is the size lesion.

Cirrhosis is the main risk factor for HCC occurence. In France, HCC screening has been establish for cirrhotic patients with hepatic ultrasound and alfa-fetoprotein measurement with the aim of detected HCC when the size allows a curative treatment.

When a nodule is discovered during the follow-up, HCC diagnosis is done following the recommendations of European Association for the Study of the Liver (AESL) in 2000, updated by the American Association for the Study of Liver Diseases (AASLD)in 2005. Diagnostic is function of nodule feature on one or two enhanced imaging techniques among CTscanner, MRI and enhanced contrast ultrasound.

This diagnostic strategy raises several questions. First, neither the most efficient dynamic imaging association for nodules from 1 to 2 cm, nor the most efficient imaging examination for nodules from 2 to 3 cm are known. Second, only few studies have been carried out about imaging semiology of the small hepatocellular carcinoma. Thus, the imprecisions of the present recommendations regarding the choice of the best examination technique and the difficulties in the diagnosis of benign or malignant nature for small nodule can lead to a bad management of these patients.

Study Type

Interventional

Enrollment (Anticipated)

450

Phase

Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

France
- - Angers, France
    - CHU Angers
  - Bordeaux, France, 33300
    - Hôpital Saint-André
  - Caen, France, 14033
    - CHU
  - Clichy, France, 92110
    - Hôpital Beaujon
  - Créteil, France, 94010
    - Hopital Henri Mondor
  - Dijon, France, 21079
    - Hôpital du Bocage
  - Grenoble, France, 38043
    - CHU
  - Lyon, France, 69317
    - Hôpital de la Croix Rousse
  - Lyon, France, 69437
    - Hôpital E. Herriot
  - Montpellier, France, 34295
    - Hôpital Saint Eloi
  - Nancy, France, 54500
    - Hôpital Brabois
  - Nantes, France, 44093
    - Hopital Hotel Dieu
  - Nice, France, 06003
    - Hôpital ARCHET II
  - Paris, France, 75012
    - Hopital Saint Antoine
  - Pessac, France, 33604
    - Hôpital Haut-Lévêque
  - Rennes, France, 35033
    - Hopital Pontchaillou
  - Saint Étienne, France, 42055
    - Hopital Nord
  - Villejuif, France, 94804
    - Hôpital Paul Brousse
  - Villejuif, France, 94805
    - Institut Gustave Roussy

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

age > 18 hears
presence of one or several nodules < 3 cm
known or suspected cirrhosis

Exclusion Criteria:

psychiatric disease
contraindication to one of the 3 imaging examinations (CTscanner, MRI, enhanced contrast ultrasound
patient already treated by chemoembolization
recurrence on the coagulation zone of a nodule already treated by per-cutaneous tumour destruction
presence of a tumour (> 3 cm) associated to the nodule
pregnant woman or breast-feeding woman

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Primary Purpose: Diagnostic
Allocation: N/A
Interventional Model: Single Group Assignment
Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Report of proportion of the positives truths and the positive wrong for an examination Time Frame: one year	one year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Angers

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2009

Primary Completion (Anticipated)

March 1, 2010

Study Registration Dates

First Submitted

February 20, 2009

First Submitted That Met QC Criteria